AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV)…
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?
Record-breaking cross-border deals helped make some formerly loss-making Chinese biotech companies profitable in the first half of the…
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
Quick Read Abbott (ABT) is down 23% year to date with insiders buying near $92; Pfizer (PFE) pairs…
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Quick Read Pfizer’s 7% yield and forward P/E of 8 complement Viatris’s three FDA PDUFA decisions arriving before…
2 Dirt Cheap Healthcare Stocks to Buy in July
Quick Read NVO trades at a forward P/E of 14 and PFE at just 8x, making both the…
This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
Quick Read PFE’s 7.27% yield looks safe on a 53% adjusted payout ratio, but free cash flow fell…
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It…
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery cofounders Josh Meier (left) and Jack Dent Cody Pickens for Forbes L ast June, when AI…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That’s normal for a pharmaceutical…
The Most Important Healthcare Stock You’re Not Watching
A company with a $140 billion market cap is very large. It is also highly likely to be…
Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers?
Pfizer (NYSE: PFE) is in a difficult spot right now. It has a number of blockbuster drugs nearing…